ATE483472T1 - Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten - Google Patents
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheitenInfo
- Publication number
- ATE483472T1 ATE483472T1 AT03756297T AT03756297T ATE483472T1 AT E483472 T1 ATE483472 T1 AT E483472T1 AT 03756297 T AT03756297 T AT 03756297T AT 03756297 T AT03756297 T AT 03756297T AT E483472 T1 ATE483472 T1 AT E483472T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- binding proteins
- immune diseases
- cd16a binding
- cd16a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38468902P | 2002-05-30 | 2002-05-30 | |
| US43932003P | 2003-01-10 | 2003-01-10 | |
| PCT/US2003/017111 WO2003101485A1 (en) | 2002-05-30 | 2003-05-29 | Cd16a binding proteins and use for the treatment of immune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE483472T1 true ATE483472T1 (de) | 2010-10-15 |
Family
ID=29715346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03756297T ATE483472T1 (de) | 2002-05-30 | 2003-05-29 | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7351803B2 (de) |
| EP (1) | EP1513554B9 (de) |
| JP (1) | JP4524181B2 (de) |
| AT (1) | ATE483472T1 (de) |
| AU (1) | AU2003232456B2 (de) |
| BR (1) | BR0311471A (de) |
| CA (1) | CA2487932A1 (de) |
| DE (1) | DE60334453D1 (de) |
| WO (1) | WO2003101485A1 (de) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487932A1 (en) * | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| DE60318065T2 (de) * | 2002-06-07 | 2008-11-20 | Trillium Therapeutics Inc., Toronto | Fcyriia-transgenes tiermodell für autoimmunkrankheit |
| AU2004204817C1 (en) | 2003-01-13 | 2011-01-20 | Macrogenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
| DK1639014T3 (da) * | 2003-06-13 | 2011-01-17 | Biogen Idec Inc | Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf |
| AU2011224032B2 (en) * | 2003-06-13 | 2013-01-31 | Biogen Ma Inc. | Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| JP4691650B2 (ja) * | 2004-03-04 | 2011-06-01 | 国立大学法人広島大学 | ニワトリ型モノクローナル抗体の生産方法、および当該生産方法によって生産されるニワトリ型モノクローナル抗体 |
| WO2005120571A2 (en) * | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| JP4839583B2 (ja) * | 2004-07-15 | 2011-12-21 | 和光純薬工業株式会社 | ＦｃγレセプターＩＩＩａに特異的な抗体およびそれを用いたＦｃγレセプターＩＩＩａの測定方法 |
| AU2005287406B2 (en) * | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| RU2481356C2 (ru) | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
| WO2006081171A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| CA2614766A1 (en) * | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods of treating autoimmune disease using humanized anti-cd16a antibodies |
| JP2009529331A (ja) * | 2006-03-10 | 2009-08-20 | マクロジェニクス，インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| WO2009077483A1 (en) | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| EP2158221B1 (de) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Kovalente diabodies und deren verwendung |
| EP2230300A4 (de) * | 2007-10-24 | 2012-08-08 | Otsuka Chemical Holdings Co Ltd | Polypeptid mit verbesserter effektorfunktion |
| WO2009117030A2 (en) * | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
| WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| EP3153526B1 (de) | 2008-01-31 | 2020-09-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antikörper gegen humanes cd39 und verwendung davon zur hemmung der regulatorischen t-zell-aktivität |
| CN106349390B (zh) | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
| SG189730A1 (en) | 2008-04-02 | 2013-05-31 | Macrogenics Inc | Her2/neu-specific antibodies and methods of using same |
| WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| US8394924B2 (en) * | 2008-10-23 | 2013-03-12 | Massachusetts Institute Of Technology | Directed engagement of activating Fc receptors |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| EP2427212B1 (de) | 2009-05-08 | 2017-08-23 | Vaccinex, Inc. | Anti-cd100-antikörper und anwendungsverfahren dafür |
| MX2012004029A (es) | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| ES2667100T3 (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
| EP2611832B1 (de) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13-antikörper und verfahren zu ihrer verwendung |
| EP2663647A4 (de) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | Aldehydmarkierte immunoglobulinpolypeptide und verwendungsverfahren dafür |
| US9376495B2 (en) | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US9890213B2 (en) | 2012-03-02 | 2018-02-13 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| CA2906566C (en) | 2013-03-14 | 2024-09-10 | Macrogenics, Inc. | Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor |
| US9243068B2 (en) | 2013-06-25 | 2016-01-26 | Vaccinex, Inc. | Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases |
| UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
| EP2840091A1 (de) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser |
| EP2839842A1 (de) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| KR102308597B1 (ko) * | 2013-10-17 | 2021-10-01 | 내셔널 유니버시티 오브 싱가포르 | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CN106103476B (zh) | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| ES2772817T3 (es) | 2014-04-10 | 2020-07-08 | Obi Pharma Inc | Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos |
| US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| KR20250007689A (ko) | 2014-09-16 | 2025-01-14 | 이나뜨 파르마 에스.에이. | 림프구에서의 억제 경로의 중화 |
| WO2016054101A1 (en) | 2014-09-29 | 2016-04-07 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| WO2016055609A1 (en) | 2014-10-10 | 2016-04-14 | Innate Pharma | Cd73 blockade |
| EP3209687A1 (de) | 2014-10-23 | 2017-08-30 | Innate Pharma | Behandlung von krebs mit anti-nkg2a-mitteln |
| MX386491B (es) | 2015-03-09 | 2025-03-18 | argenx BV | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. |
| CN114533867A (zh) * | 2015-03-27 | 2022-05-27 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| ES2958720T3 (es) | 2015-06-10 | 2024-02-13 | Immunitybio Inc | Células NK-92 modificadas para tratar el cáncer |
| TWI870335B (zh) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| SMT202100280T1 (it) | 2016-01-21 | 2021-07-12 | Innate Pharma | Neutralizzazione delle vie inibitorie nei linfociti |
| AR108034A1 (es) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| CN108699158B (zh) | 2016-03-08 | 2022-06-03 | 依奈特制药公司 | Siglec中和抗体 |
| WO2017157948A1 (en) | 2016-03-14 | 2017-09-21 | Innate Pharma | Anti-cd39 antibodies |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| CA3019398A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| WO2018083080A2 (en) | 2016-11-04 | 2018-05-11 | Innate Pharma | Nkp46 ligand |
| BR112019012950A2 (pt) | 2016-12-23 | 2019-11-26 | Macrogenics, Inc. | molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo |
| WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| AU2018235092B2 (en) | 2017-03-16 | 2024-09-19 | Innate Pharma | Compositions and methods for treating cancer |
| CN111263769B (zh) | 2017-07-10 | 2024-01-02 | 先天制药公司 | Siglec-9中和性抗体 |
| WO2019011852A1 (en) | 2017-07-10 | 2019-01-17 | Innate Pharma | POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| TWI924623B (zh) | 2018-03-13 | 2026-05-11 | 法商天賜製藥公司 | 頭頸癌之治療 |
| IT201800004853A1 (it) | 2018-04-24 | 2019-10-24 | Metodi per trattare il cancro | |
| WO2019219658A1 (en) | 2018-05-15 | 2019-11-21 | Medimmune Limited | Treatment of cancer |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| TWI870353B (zh) | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| MX2020013068A (es) * | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
| KR102907902B1 (ko) | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
| US20200376135A1 (en) * | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| CN113330033B (zh) | 2018-12-26 | 2024-11-29 | 先天制药公司 | 白细胞免疫球蛋白样受体2中和性抗体 |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| KR20220002959A (ko) | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
| WO2020225552A1 (en) | 2019-05-06 | 2020-11-12 | Medimmune Limited | Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer |
| BR112021024632A2 (pt) | 2019-06-07 | 2022-01-18 | Argenx Bvba | Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea |
| US12698331B2 (en) | 2019-12-10 | 2026-08-04 | Institut Pasteur | Antibody blocking human FcγRIIIA and FcγRIIIB |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| KR20230050378A (ko) | 2020-08-13 | 2023-04-14 | 이나뜨 파르마 에스.에이. | 항-cd73 항체를 사용하여 암을 치료하는 방법 |
| US20240101677A1 (en) * | 2021-01-27 | 2024-03-28 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
| JP2024524378A (ja) * | 2021-06-29 | 2024-07-05 | 山▲東▼先声生物制▲薬▼有限公司 | Ｃｄ１６抗体及びその応用 |
| US20240352128A1 (en) * | 2021-08-25 | 2024-10-24 | Nanjing GenScript Biotech Co., Ltd. | ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a |
| CA3223956A1 (en) | 2021-12-20 | 2023-06-29 | Vetoquinol Sa | Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof |
| CN114805592A (zh) * | 2022-05-13 | 2022-07-29 | 南京吉盛澳玛生物医药有限公司 | 一种三特异性抗体的设计、制备及用途 |
| WO2023227660A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| CN115960234B (zh) * | 2022-10-27 | 2023-12-29 | 合肥天港免疫药物有限公司 | 抗cd16a的抗体及其应用 |
| JP2026504499A (ja) * | 2023-02-06 | 2026-02-05 | レプ バイオファーマ カンパニー， リミテッド | 抗ｃｄ１６ａ抗体およびその使用 |
| WO2025114614A1 (en) | 2023-11-30 | 2025-06-05 | Vetoquinol Sa | Anti-canine interleukine-4-receptor alpha (il-4rα) antibodies and the uses thereof |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| WO2025218645A1 (zh) * | 2024-04-16 | 2025-10-23 | 深圳众格生物科技有限公司 | 抗cd16a抗体及其用途 |
| WO2025229206A1 (en) | 2024-05-03 | 2025-11-06 | argenx BV | Monovalent anti-iga binding molecules and methods of use |
| WO2025233266A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd39 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946788A (en) * | 1985-06-11 | 1990-08-07 | Ciba-Geigy Corporation | Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| FR2611913B1 (fr) | 1987-02-24 | 1994-04-15 | Khayat David | Procede de dosage des recepteurs fc gamma solubles seriques, coffret de dosage correspondant et applications |
| JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JPH02500329A (ja) * | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| ATE321134T1 (de) | 1988-05-27 | 2006-04-15 | Applied Research Systems | Menschlicher fc-gamma-rezeptor iii |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5437994A (en) * | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
| US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| ES2246502T3 (es) * | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6027725A (en) * | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2126967A1 (en) * | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| JPH08511241A (ja) * | 1993-04-08 | 1996-11-26 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ２−アミノイミダゾールとアルデヒドから４−および／または５−（ジ）置換された２−アミノイミダゾールを合成するための方法 |
| US5641863A (en) * | 1993-09-30 | 1997-06-24 | University Of Pennsylvania | Chimeric IgG Fc receptors |
| AU707440B2 (en) | 1994-03-29 | 1999-07-08 | Celltech Therapeutics Limited | Antibodies against E-selectin |
| DE19619068A1 (de) * | 1996-05-13 | 1997-11-27 | Siemens Ag | Vorrichtung zur Überwachung des Transportprozesses von flachen Sendungen |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6025158A (en) * | 1997-02-21 | 2000-02-15 | Genentech, Inc. | Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP1356052B1 (de) | 2000-12-14 | 2008-08-20 | Genentech, Inc. | Produktion von ganzen Antikörpern in prokaryontischen Zellen |
| CA2487932A1 (en) * | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| CA2614766A1 (en) * | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods of treating autoimmune disease using humanized anti-cd16a antibodies |
-
2003
- 2003-05-29 CA CA002487932A patent/CA2487932A1/en not_active Abandoned
- 2003-05-29 DE DE60334453T patent/DE60334453D1/de not_active Expired - Lifetime
- 2003-05-29 WO PCT/US2003/017111 patent/WO2003101485A1/en not_active Ceased
- 2003-05-29 AT AT03756297T patent/ATE483472T1/de not_active IP Right Cessation
- 2003-05-29 JP JP2004508840A patent/JP4524181B2/ja not_active Expired - Fee Related
- 2003-05-29 BR BRPI0311471-6A patent/BR0311471A/pt not_active IP Right Cessation
- 2003-05-29 AU AU2003232456A patent/AU2003232456B2/en not_active Ceased
- 2003-05-29 EP EP03756297A patent/EP1513554B9/de not_active Expired - Lifetime
- 2003-05-29 US US10/449,566 patent/US7351803B2/en not_active Expired - Fee Related
-
2007
- 2007-06-04 US US11/757,932 patent/US7618628B2/en not_active Expired - Fee Related
- 2007-06-04 US US11/757,939 patent/US7838635B2/en not_active Expired - Fee Related
-
2010
- 2010-10-14 US US12/904,554 patent/US20110152504A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1513554A1 (de) | 2005-03-16 |
| DE60334453D1 (de) | 2010-11-18 |
| BR0311471A (pt) | 2007-04-27 |
| US20070244303A1 (en) | 2007-10-18 |
| JP4524181B2 (ja) | 2010-08-11 |
| EP1513554B1 (de) | 2010-10-06 |
| CA2487932A1 (en) | 2003-12-11 |
| WO2003101485A1 (en) | 2003-12-11 |
| EP1513554A4 (de) | 2006-06-28 |
| US20110152504A1 (en) | 2011-06-23 |
| US7351803B2 (en) | 2008-04-01 |
| JP2005532342A (ja) | 2005-10-27 |
| US7618628B2 (en) | 2009-11-17 |
| AU2003232456B2 (en) | 2009-06-04 |
| US20040010124A1 (en) | 2004-01-15 |
| HK1074991A1 (en) | 2005-12-02 |
| EP1513554B9 (de) | 2011-11-09 |
| AU2003232456A1 (en) | 2003-12-19 |
| US20080050371A1 (en) | 2008-02-28 |
| US7838635B2 (en) | 2010-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60334453D1 (de) | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten | |
| MX2008000030A (es) | Metodos para el tratamiento de enfermedad autoinmune utilizando anticuerpos anti-cd16a humanizados. | |
| ZA202102223B (en) | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| WO2003078600A3 (en) | Human monoclonal antibodies to influenza m2 protein and methods of making and using same | |
| WO2004083249A3 (en) | Antibodies against human il-21 receptor and uses therefor | |
| ATE480562T1 (de) | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese | |
| DE60231316D1 (de) | VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN | |
| EA200700847A1 (ru) | Материалы, связывающие прионные белки, и способы их применения | |
| CY1110557T1 (el) | Αντισωματα ιντερλευκινης-10 | |
| WO2004067568A3 (en) | Human il-1 beta antagonists | |
| EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
| WO2006118772A3 (en) | Fcrn antibodies and uses thereof | |
| DE69433406T2 (de) | Antikörper gegen cd40 | |
| WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
| MY146664A (en) | Antibodies against human il-22 and uses therefor | |
| ATE468755T1 (de) | Verfahren und zusammensetzungen mit molkeproteinisolaten | |
| WO2004035742A3 (en) | Sets of digital antibodies directed against short epitopes, and methods using same | |
| WO2020172621A8 (en) | Cd33 antibodies and methods of using the same to treat cancer | |
| PL378566A1 (pl) | Ligandy dla białek wiążących TGF-beta i ich zastosowania | |
| EP3995508A4 (de) | Neuartiges modifiziertes immunoglobulin-fc-fusionsprotein und verwendung davon | |
| EP4181909A4 (de) | Bispezifische antagonisten des retinolbindenden proteins 4 zur stabilisierung von transthyretintetrameren, ihre herstellung und verwendung bei der behandlung von gemeinsamen altersbedingten komorbiditäten | |
| EP4640282A3 (de) | Immunodominante proteine und fragmente bei multipler sklerose | |
| WO2019094533A8 (en) | Angptl8-binding agents and methods of use thereof | |
| GB0324656D0 (en) | A protein involved in ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |